Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). 42nd Annual Meeting of the American-Society-of-Clinical-Oncology Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., Gascoyne, R. D., Weller, E., Horning, S. J. AMER SOC CLINICAL ONCOLOGY. 2006: 422S–422S
View details for Web of Science ID 000239009402559